Finanzen von Zenas Biopharma Inc (ZBIO)ZBIOZenas Biopharma Inc

Evaluating the bottom line, Zenas BioPharma, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -7765.90%, while the net margin is -11145.60%. These profitability ratios, combined with a Return on Equity (ROE) of -199.04%, provide a clear picture of how effectively ZBIO converts its operational activities into shareholder value.

In the context of the broader market, ZBIO competes directly with industry leaders such as STOK and MRVI. With a market capitalization of $1.92B, it holds a significant position in the sector. When comparing efficiency, ZBIO's gross margin of 100.00% stands against STOK's 100.00% and MRVI's 40.14%. Such benchmarking helps identify whether Zenas BioPharma, Inc. is trading at a premium or discount relative to its financial performance.

Zenas Biopharma has shown significant revenue growth potential, with projected revenue of $10 million for Q1 2025, although it has reported net losses in recent quarters, including -$111.46 million in Q2 2026.